SPP1 expressed in malignant pleural effusion in patients with advanced lung cancer and its value for diagnosis

ZHANG He,YUAN Dong-mei,CHEN Fang-fang,BAI Cui-qing,LIU Chun-hua,SONG Yong

DOI: https://doi.org/10.3877/cma.j.issn.1674-6902.2013.03.007

2013-01-01

Abstract:Objective As a common complication of cancer,MPE significantly effect the respiratory function and survival of those patients.There is evidence accumulated that Secreted phosphoprotein-1 (SPP1 alias osteopontin) plays a key role in MPE caused by lung cancer,so our aim to find whether the expression of SPP1 in pleural effusion may be readily available diagnosis biomarker of MPE with advanced lung cancer patient.Methods A total of 96 patients with malignant pleural effusion were chose from our research center caused by lung cancer,while 24 control samples were collected from those benign lung diseases.ELISA were used to detect the contents of SPP1 from each specimen.SPSSl6.0 statistical analysis software were used for the analysis.t test analysis was used to analysis SPP1 expression level both in case group and control group,then the ROC curve was used to select the cutoff value.Results In 120 specimens of pleural effusion,SPP1 expression level in case group is 1568.9±1297.15 ng/ml(x ± s) while control group is 644.12±480.50 ng/ml(x±s).There is statistically significant difference between these two groups of SPP1 expression level (t=4.766,P<0.01).With a cutoff value of 1247.90 ng/ml(sensitivity38.54% ;specificity95.83% ;the area under the curve (AUC) 0.662;95% CI 0.554-0.770).Conclusion SPP1 levels were elevated in malignant pleural effusions,as compared with the levels in benign pleural effusions.The SPP1 level in pleural effusion might be used as a diagnositic factor in advanced lung cancer patients but the diagnostic accuracy of the tests was not sufficient to permit routine use in clinical practice.